Cite
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
MLA
Rabl, Miriam, et al. “Plasma Neurofilament Light, Glial Fibrillary Acid Protein, and Phosphorylated Tau 181 as Biomarkers for Neuropsychiatric Symptoms and Related Clinical Disease Progression.” Alzheimer’s Research & Therapy, vol. 16, no. 1, July 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s13195-024-01526-4.
APA
Rabl, M., Zullo, L., Lewczuk, P., Kornhuber, J., Karikari, T. K., Blennow, K., Zetterberg, H., Bavato, F., Quednow, B. B., Seifritz, E., von Gunten, A., Clark, C., & Popp, J. (2024). Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression. Alzheimer’s Research & Therapy, 16(1), 1–11. https://doi.org/10.1186/s13195-024-01526-4
Chicago
Rabl, Miriam, Leonardo Zullo, Piotr Lewczuk, Johannes Kornhuber, Thomas K. Karikari, Kaj Blennow, Henrik Zetterberg, et al. 2024. “Plasma Neurofilament Light, Glial Fibrillary Acid Protein, and Phosphorylated Tau 181 as Biomarkers for Neuropsychiatric Symptoms and Related Clinical Disease Progression.” Alzheimer’s Research & Therapy 16 (1): 1–11. doi:10.1186/s13195-024-01526-4.